Core Strategy - FEMSA is focused on its Forward Strategy, emphasizing long-term value creation of its core businesses and maximizing shareholder value through prudent financial management [1] Share Repurchase Agreement - The company has entered into an accelerated share repurchase (ASR) agreement to buy back $250 million of its American Depositary Shares (ADS) [2] - The ASR agreement will initially deliver 483,559 ADSs on May 20, 2025, with the total number of repurchased shares based on the daily volume-weighted average price during the agreement term [3] Capital Return Strategy - FEMSA plans to return capital to shareholders as a crucial aspect of its overall strategy, following successful divestments related to FEMSA Forward and considering expected capital needs [4] Market Performance - FEMSA's shares have gained 1.8% over the past year, contrasting with a 1.2% decline in the industry, despite facing a soft consumer environment and rising operating expenses [5] Business Segments and Growth Opportunities - The company is progressing on its FEMSA Forward Strategy to drive value in its core businesses, including Retail, Coca-Cola FEMSA, and Digital@FEMSA, while exploring potential divestments [6] - FEMSA's Proximity and Health retail businesses present significant long-term growth opportunities, with plans to accelerate earnings growth through organic expansion [7]

Financial Data and Key Metrics Changes - Total sales increased by 32% year over year, reaching $347.8 million for the quarter ended March 31, 2025 [12] - Adjusted EBITDA rose by 85%, reflecting strong operational performance [7][12] - Adjusted diluted EPS more than doubled compared to the previous year [7] Business Segment Data and Key Metrics Changes - The Animal Health segment led with a 42% revenue growth, totaling $258.4 million [12][14] - Nutritional Specialties achieved 8% revenue growth, while Performance Products saw a significant increase of 28% [9][12] - Newly integrated MSA and other products within Animal Health experienced a 68% increase in sales [8][14] Market Data and Key Metrics Changes - The company anticipates some pressure on certain inputs and markets in the range of $5 million to $10 million due to tariffs in fiscal year 2026 [10] - The overall performance in international markets was stable, with limited impact from foreign exchange fluctuations [44] Company Strategy and Development Direction - The "Fiber Forward" strategy focuses on disciplined operations and continuous improvement, contributing to current performance [9][10] - The company is making targeted investments in procurement and supply chain resilience to manage potential disruptions [10][20] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in navigating external challenges, including tariffs, without significant impact on financial results for the remainder of fiscal year 2025 [10][22] - The updated guidance reflects solid execution and continued momentum, with net sales expected between $1.26 billion and $1.29 billion [11][20] Other Important Information - The company generated $49 million of positive free cash flow for the twelve months ended March 31, 2025 [17] - Cash and cash equivalents were $70 million at the end of the quarter [17] Q&A Session Summary Question: Can you elaborate on the company's exposure to upcoming pharma tariffs? - Management indicated that most manufacturing is done in the U.S., with some inputs sourced from other markets, and they have implemented measures to mitigate tariff impacts [25][27] Question: What drove the slower growth in the Medicaid fee added business? - The decline was attributed to the timing of orders from larger customers, with overall year-to-date growth remaining positive [28][29] Question: What factors are driving the increase in guidance for EBITDA and EPS? - The increase is driven by a favorable mix, strong vaccine performance, and contributions from the Zoetis MFA portfolio [32][35] Question: Can you provide more details on the specific products affected by tariffs? - The impact is primarily from inputs subject to general tariffs rather than specific products from China [38] Question: Is the company lobbying for exceptions from potential pharma tariffs? - Management confirmed involvement in lobbying efforts for exceptions, emphasizing the importance of these products in food pricing [42] Question: What was the FX impact for the quarter? - Limited impact was noted, with efforts to transact in U.S. dollars to minimize foreign exchange effects [44]

Flex (FLEX) Q4 2025 Earnings Call May 07, 2025 08:30 AM ET Speaker0 Thank you for standing by. Welcome to Flex's Fourth Quarter and Fiscal Year twenty twenty five Earnings Conference Call. Presently, all participants are in a listen only mode. After the speakers' remarks, there will be a question and answer session. As a reminder, this call is being recorded. I will now turn the call over to Mr. David Rubin. You may begin. Speaker1 Thank you, Melissa. Good morning, welcome to Flex's fourth quarter and fisca ...

Fomento Economico Mexicano S.A.B. de C.V. (FMX) , alias FEMSA, shares have rallied 24.3% in the year-to-date period. With this rise, FMX shares have outperformed the broader industry and the Consumer Staples sector’s growth of 10.7% and 5.7%, respectively. The company’s shares have also surpassed the S&P 500’s decline of 12.6% in the same period.FMX’s YTD Stock Performance Image Source: Zacks Investment Research At the current price of $106.23, the FMX stock trades at a 13.7% discount to its 52-week high of ...